We are live on ! Find out more
SBIO icon

ALPS Medical Breakthroughs ETF

62.54 USD
-1.17
1.84%
At close Updated Sep 15, 4:00 PM EDT
1 day
-1.84%
5 days
-5.57%
1 month
-7.79%
3 months
16.9%
6 months
23.43%
Year to date
24.68%
1 year
75.23%
5 years
34.96%
10 years
142.22%

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 63.6%
Neutral 36.4%
Negative 0%
Neutral
Zacks Investment Research
7 days ago
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the ALPS Medical Breakthroughs ETF (SBIO), a passively managed exchange traded fund launched on December 31, 2014.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
Neutral
Seeking Alpha
26 days ago
Sabio Holdings Inc. (SBIO:CA) Q2 2026 Earnings Call Transcript
Sabio Holdings Inc. (SBIO:CA) Q2 2026 Earnings Call Transcript
Sabio Holdings Inc. (SBIO:CA) Q2 2026 Earnings Call Transcript
Positive
ETF Trends
29 days ago
3 Small-Cap ETFs to Watch as Russell 2000 Hits Record
The Russell 2000 closed at a new record high Friday amid continued upwards momentum for several market indexes. That index, with its focus on small-caps, could prove an intriguing source of investing opportunities, given the right approach.
3 Small-Cap ETFs to Watch as Russell 2000 Hits Record
Neutral
ETF Trends
1 month ago
Risk-Wary Family Offices Double Down on Infrastructure
Geopolitical shocks have pushed family offices to rethink nearly every corner of their portfolios. Infrastructure has emerged as the asset class they trust most right now.
Risk-Wary Family Offices Double Down on Infrastructure
Positive
ETF Trends
2 months ago
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Neutral
Zacks Investment Research
2 months ago
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the ALPS Medical Breakthroughs ETF (SBIO) is a passively managed exchange traded fund launched on December 31, 2014.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
Positive
Seeking Alpha
2 months ago
SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn
ALPS Medical Breakthroughs ETF targets late-stage clinical trial biotechs primed for outsized performance and M&A. SBIO's selective criteria focus on U.S.-listed firms with strong cash positions, Phase 2/3 assets, and near-term catalysts, creating a portfolio of high-volatility, high-alpha 'lottery tickets.' SBIO has delivered 111% returns over the past year, outperforming the S&P 500; its holdings have seen notable buyouts and clinical milestones.
SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn
Positive
ETF Trends
2 months ago
Biotech Gives SBIO Its Best Month Since 2023
Biotech stocks delivered their best single month since late 2023 in June, carrying the ALPS Medical Breakthroughs ETF (SBIO) to one of the top returns across the ALPS lineup. Key Takeaways: SBIO returned 18.7% in June, its best single month since December 2023.
Biotech Gives SBIO Its Best Month Since 2023
Positive
ETF Trends
2 months ago
June's Top ETFs: Biotech & China Semiconductors Surge
June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out of the five top-performing equity ETFs as of June 29.
June's Top ETFs: Biotech & China Semiconductors Surge
Positive
ETF Trends
2 months ago
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
Biotech ETF Index Surges 10% After Rebalance
Price charts implemented using Lightweight Charts™